- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00256113
An Eight-week Study to Evaluate the Efficacy and Safety of Saredutant in Patients With Depression
An Eight-Week, Multicenter, Double-blind, Placebo-controlled Study Evaluating the Efficacy, Safety, and Tolerability of One Fixed 100 mg Dose of Saredutant in Patients With Major Depressive Disorder
The purpose of the study is to evaluate the efficacy and safety of saredutant (or SR48968C) in patients with depression.
The primary objective is to evaluate the efficacy of a 100 mg dose of saredutant compared to placebo in patients with depression.
The secondary objectives are to evaluate the safety of saredutant, to evaluate the efficacy of saredutant on disability and quality of life in patients with depression, and to evaluate blood levels of saredutant.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Actual)
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
-
Laval, Canada
- Sanofi-Aventis Administrative Office
-
-
-
-
-
Santiago, Chile
- Sanofi-Aventis Administrative Office
-
-
-
-
-
Zagreb, Croatia
- Sanofi-Aventis Administrative Office
-
-
-
-
-
Praha, Czechia
- Sanofi-Aventis Administrative Office
-
-
-
-
-
Tallinn, Estonia
- Sanofi-Aventis Administrative Office
-
-
-
-
-
Berlin, Germany
- Sanofi-Aventis Administrative Office
-
-
-
-
-
Mexico, Mexico
- Sanofi-Aventis Administrative Office
-
-
-
-
-
Porto Salvo, Portugal
- Sanofi-Aventis Administrative Office
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- 1. Male or female patients.
- 2. 18 to 64 years of age.
- 3. Inpatients or outpatients.
- 4. Written informed consent from the patient and/or legally authorized representative.
- 5. Able to comply with the protocol and follow written and verbal instructions.
- 6. Subjects of childbearing potential must have a confirmed negative serum b-hCG test prior to entry into Segment B and must employ an acceptable method of birth control (e.g., oral, depot, or implanted contraceptive method, IUDs, sterilization, barrier methods in conjunction with spermicide).
- 7. Diagnosis of major depressive disorder, as defined by Diagnostic and Statistical Manual of Mental Disorders, 4th edition, Text Revision criteria and confirmed by the semi-structured Mini International Neuropsychiatric Interview (MINI), recurrent episode for at least one month prior to the entry.
- 8. Minimum total score of 22 on the Montgomery-Asberg Depression Rating Scale (MADRS).
Exclusion Criteria:
- 1. Patients whose current depressive episode is diagnosed with psychotic features, catatonic features, seasonal pattern or post-partum onset.
- 2. The duration of the current depressive episode is greater than 2 years.
- 3. Patients who are currently suicidal or have a history of a suicide attempt within 3 years prior to entry.
- 4. Patients whose current depressive episode is secondary to a general medical disorder.
- 5. Patients with a history or presence of bipolar disorders or psychotic disorders according to the D and L criteria of the MINI.
- 6. Patients with alcohol dependence or abuse or substance dependence or abuse in the past 12 months except nicotine or caffeine dependence.
- 7. Patients with a history of failure to respond to treatment with paroxetine or other antidepressant medications.*
- 8. Patients who have used the following prior to entry into Segment B: any antipsychotic within 3 months,-fluoxetine within 35 days, -any monoamine oxidase inhibitor within 21 days, any other antidepressant, anxiolytic, sedative-hypnotic, or mood-stabilizer (lithium, anticonvulsants) within 7 days except permitted concomitant medications.
- 9. Females who are pregnant or breast-feeding.
- 10. Severe or unstable cardiovascular, renal, hepatic, respiratory, hematological, endocrinological, neurological, or other somatic disease that might interfere with the evaluation of study medication.
- 11. History of seizures other than a single childhood febrile seizure.
- 12. ECG abnormalities of potential clinical significance including a QT interval with Bazett's correction of 500 msec or more at entry.
- 13. Use of known inducers or potent inhibitors of CYP3A4 within 7 days of entry.
- 14. Use of drugs with known risk for Torsade de Pointes within 7 days of entry into Segment B.
- 15. Participation in a clinical trial of an experimental therapy within 30 days prior to entry or prior participation in a clinical trial of saredutant.
- 16. Patients with a positive HbsAg or anti-HCV antibody test at screening.
- 17. Patients with any of the following at screening: ALT >2 times the upper limit of the normal range (XULN), AST >2XULN, GGT >3XULN, total or conjugated bilirubin >ULN
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
---|
The primary outcome of the study is the change from baseline to Day 56 of treatment in the Hamilton Depression Rating Scale (HAM-D) total score.
|
Secondary Outcome Measures
Outcome Measure |
---|
The main secondary outcomes are the changes from baseline to Day 56 of treatment in the HAM-D depressed mood item, the Montgomery Asberg Depression Rating Scale total, and the Clinical Global Impression Severity of Illness scores.
|
Collaborators and Investigators
Sponsor
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- EFC5575
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Depressive Disorder
-
York UniversityCentre for Addiction and Mental HealthSuspendedDisorder, Major DepressiveCanada
-
Samsung Medical CenterUnknownMajor Depressive Disorder, Anxiety DisorderKorea, Republic of
-
Seasons Biotechnology (Taizhou) Co., Ltd.CompletedMajor Depressive Disorder (MDD)India
-
Repurposed Therapeutics, Inc.Unknown
-
GlaxoSmithKlineCompletedMajor Depressive Disorder (MDD)United States
-
Shalvata Mental Health CenterUnknownMAjor Depressive DisorderIsrael
-
Wyeth is now a wholly owned subsidiary of PfizerCompletedDepressive Disorder, Major Depressive DisorderUnited States
-
Seasons Biotechnology (Taizhou) Co., Ltd.CompletedMajor Depressive Disorder (MDDIndia
-
Gangnam Severance HospitalCompletedMajor Depressive Disorder(MDD)Korea, Republic of
-
University College, LondonCompletedUnipolar Major Depressive DisorderUnited Kingdom
Clinical Trials on Saredutant succinate (SR48968C)
-
SanofiCompletedDepressive DisorderFrance, Canada, Germany, Portugal, Czech Republic, Mexico, Croatia, Chile
-
SanofiCompletedDepressive DisorderUnited States
-
SanofiCompletedDepressive DisorderUnited States
-
SanofiCompletedDepressive DisorderUnited States
-
SanofiCompletedDepressive DisorderUnited States
-
SanofiCompletedGeneralized AnxietyUnited States, Australia
-
SanofiCompletedDepressive DisorderUnited States
-
SanofiCompleted
-
Changchun Huayang High-tech Co., LtdBeijing Bionovo Medicine Development Co., Ltd.UnknownAlzheimer's DiseaseChina
-
Hutchison Medipharma LimitedUnknown